Bruker Daltonics Announces CRADA with Battelle's PNNL for Continued Development of FTMS for Proteomics Research.Business Editors/Health/Medical Writers MONTREAL--(BUSINESS WIRE)--June 9, 2003 At the 51st Annual Conference on Mass Spectrometry and Allied Topics, Bruker Daltonics Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BDAL BDAL Battle Doll Angelic Layer (game) ) announces the formation of a Cooperative Research and Development Agreement “CRADA” redirects here. For other uses, see CRADA (disambiguation). A Cooperative Research and Development Agreement (CRADA) is an agreement between a government agency and a private company to work together. (CRADA CRADA Cooperative Research And Development Agreement ) with Battelle Memorial Institute The Battelle Memorial Institute is a private not-for-profit applied science and technology development company headquartered in Columbus, Ohio. The institute opened in 1929 but traces its origins to the 1923 will of Ohio industrialist Gordon Battelle which provided for its , Operating and Management Contractor for the Department of Energy's Pacific Northwest National Laboratory The Pacific Northwest National Laboratory (PNNL) is one of nine United States Department of Energy (DOE) multiprogram national laboratories. The laboratory PNNL is located in Richland, Washington, and operates a marine research facility in Sequim, Washington. (PNNL). This follow-on CRADA will focus on the further development and commercialization of methods for enhancing the dynamic range of Fourier transform mass spectrometry (FTMS) for high-throughput proteomics research. The technique known as Dynamic Range Enhancement for Advanced Mass Spectrometry (DREAMS), originally developed by Dr. Richard Smith's group in the Environmental Molecular Sciences Laboratory (EMSL) at PNNL, will be the basis of the research. The new CRADA provides PNNL with Bruker Daltonics' new APEX(TM)-Q hybrid FTMS to improve research capabilities at the EMSL, and to facilitate the transfer of DREAMS to a commercial instrument. This latest endeavor is the second CRADA between Bruker Daltonics and Battelle/PNNL. In 2000, the two groups signed a first CRADA on the co-development of a highly sensitive, hybrid Q-q-FTMS system for data-dependent proteomics research. This first CRADA helped Bruker Daltonics form the basis of the successful new APEX-Q FTMS for "shot gun" proteomics. The Q-q front end of the APEX-Q permits not only easy on-the-fly ion dissociation for MS/MS MS/MS Tandem Mass Spectroscopy MS/MS Multistage Mass Spectrometry experiments, but importantly can also increase the dynamic range in proteomics experiments dramatically. The combined HPLC HPLC high-performance liquid chromatography. HPLC high performance liquid chromatography. HPLC High-performance liquid chromatography Lab instrumentation A highly sensitive analytic method in which analytes are placed Q-q-FTMS high-field system, including a 9.4 or 12 Tesla magnet, is expected to be able to analyze enzymatic peptides with a dynamic range of 10,000 to 100,000, while retaining the extremely high resolution and excellent mass accuracy of FTMS. It is often the low abundance proteins that can be of considerable interest in biological research, as well as in drug or diagnostics discovery, and high-field Q-q-FTMS facilitates their study in a very straight-forward manner. Paul Speir, Ph.D., Asst. Vice President of Bruker Daltonics, stated: "Our original CRADA with PNNL was extremely fruitful and helped produce a breakthrough commercial high-field hybrid FTMS system for 'shot-gun' and 'top-down' proteomics. We are very excited to continue this work with Dr. Smith and his group at PNNL to advance the FTMS tools for high-throughput and high-information-content proteomics research even further." ABOUT BRUKER DALTONICS AND EMSL Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information about Bruker Daltonics, please visit www.bdal.com or www.bdal.de . The William R. Wiley Environmental Molecular Sciences Laboratory (EMSL) is a Department of Energy scientific user facility located at PNNL. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to technological approaches, product development, manufacturing, market acceptance, cost and pricing of Bruker Daltonics' products, dependence on collaborative partners, suppliers, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and other risk factors discussed from time to time in Bruker Daltonics' reports or filings with the Securities and Exchange Commission. Bruker Daltonics expressly disclaims any obligation to update the information contained herein. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion